The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
ApexOnco Front Page
Recent articles
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
The company will license EGFR and cMet inhibitors from Celyn.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
After several discontinuations, a new ADC enters the clinic.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
